NasdaqGS:MRNABiotechs
Moderna (MRNA) Could Be 238% Overvalued On Melanoma Trial Progress
Moderna (MRNA) is back in focus after releasing positive Phase 3 topline results for intismeran autogene, its individualized mRNA cancer therapy, in combination with Merck’s KEYTRUDA in resected high risk melanoma.
For investors, the positive Phase 3 data arrives after a period of sharp volatility in Moderna’s stock. The latest US$149.66 share price comes after a 1 month share price return of 169.03% and a year to date share price return of 384.96%. The 1 year total shareholder return of...